Abstract:

Tuberculosis (TB), a chronic infectious disease caused by Mycobacterium tuberculosis, is a major global public health issue.China faces a substantial TB burden and signiflcant challenges related to drug resistance.Early identiflcation, pathogen-based diagnosis and standardized treatment of pulmonary TB patients are critical to reducing transmission, mortality and the emergence of drug resistance.To enhance the quality of TB diagnosis and treatment, the National Medical Quality Control Center for Infectious Diseases has established a series of quality control indicators for pulmonary TB.These indicators cover the referral rate of TB patients in non-TB-designated medical institutions, as well as key aspects in TB-designated hospitals, including the pathogen-positive rate, drug resistance screening rate for pathogen-positive patients,utilization rate of standardized treatment regimens, standardized diagnosis rate for pathogen-negative patients,and the proper management rate of adverse drug reactions.This consensus proposes methods for indicators monitoring, data collection requirements, and recommendations for continuous quality improvement, aiming to achieve scientific, precise and standardized TB care, thereby reducing the risk of TB transmission and mortality.

Key words: Pulmonary tuberculosis, Healthcare quality, Designated medical institutions, Expert consensus